### Highlights of This Issue 6393

#### SPECIAL FEATURES

**CCR Translations**

6395  Assessing Iron Overload: Are We There Yet?  
Paul C. Kruger, Michael F. Leahy, and John K. Olynyk  
*See article p. 6460*

6398  Improving Publication Rates of Biomarker Results from Cancer Trials  
Robert Iannone  
*See article p. 6478*

**Molecular Pathways**

6400  Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement  
Benjamin H. Lok and Simon N. Powell

**Review**

6407  *p53 Arg22Pro* Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis  
Steven Habbous, Vincent Pang, Lawson Eng, Wei Xu, Goldie Kurtz, Fei-Fei Liu, Helen Mackay, Eitan Amir, and Geoffrey Liu

**HUMAN CANCER BIOLOGY**

6416  Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9  
Mei-Hsuan Lu, Chao-Cheng Huang, Mei-Ren Pan, Hong-Hwa Chen, and Wen-Chun Hung

---

**CANCER THERAPY: PRECLINICAL**

6426  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping  
Julia D. Wallkuhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Marialena Pierobon, Jianguo Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhor, Heinz Höfler, Laura Eserman on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Liotta, Karl-Friedrich Becker, and Emanuel F. Petricoin III

6436  Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies  
Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, and Eduardo Davila

6446  Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma  
Martin K. Hunn, Kathryn J. Farrand, Kate W.R. Broadley, Robert Weinkove, Peter Ferguson, Rose J. Miller, Cameron S. Field, Troels Petersen, Melanie J. McConnell, and Ian F. Hermans

**IMAGING, DIAGNOSIS, PROGNOSIS**

6456  MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation  
Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, Malte von Bonin, Claudia Schönefeldt, Sabine Mair, Verena Plodeck, Michael Laniado, Gunter Weiss, Johannes Schetelig, Gerhard Ehninger, Igor Theurl, Martin Bornhauser, and Uwe Platzbecker  
*See commentary p. 6395*

6469  Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging  
Thomas Nielsen, Lise Bentzen, Michael Pedersen, Trine Tramm, Paul F.J.W. Rijken, Johan Bussink, Michael R. Horsman, and Leif Ostergaard
CANCER THERAPY: CLINICAL

6478 Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials
Georgina A. Freeman and Jonathan Kimmelman
See commentary p. 6398

6485 Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Paola Filipazzi, Lorenzo Pilla, Luigi Mariani, Roberto Patuzzo, Chiara Castelli, Chiara Carnisacchi, Andrea Maurichi, Agata Cova, Gianluigi Rigamonti, Felicetta Giardino, Annabella Di Florio, Marco Asoli, Paola Frati, Gloria Sovena, Paola Squarzina, Michele Maio, Riccardo Danielli, Vanna Chiarion-Sileni, Antonello Villa, Claudia Lombardo, Gabrina Tragni, Mario Santinami, Giorgio Parmiani, and Licia Rivoltini

6497 Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6519 Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Yunfeng Cui, Jacqueline A. Brosnan, Amanda L. Blackford, Sarojit Sur, Ralph H. Hruban, Kenneth W. Kinzler, Bert Vogelstein, Anirban Maitra, Luis A. Diaz Jr, Christine A. Iacobuzio-Donahue, and James R. Eschleman

6531 Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

6542 Acknowledgment to Reviewers

ABOUT THE COVER

Expression of GFP-tagged PROX1 in colon cancer cells reduced E-cadherin and induced epithelial–mesenchymal transition. We found that PROX1 activated miR-9 expression to attenuate E-cadherin protein posttranscriptionally. Results of this study provide a molecular basis by which PROX1 promotes tumorigenesis of colon cancer. For details, see the article by Lu and colleagues on page 6416 of this issue.
Clinical Cancer Research

18 (23)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/23

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.